Avoid statins in patients with intracerebral hemorrhageUncertain whether statins advisable in patients at high risk for ICH. New drugs get a rise out of HDLPhase II trials look promising, but larger outcome studies needed Cholesterol deposits on eyelids give insight into heart disease The eyes have it—a clue to heart disease, that is. Stillbirth and repeat miscarriages carry heart attack risk Thelin (sitaxsentan): PAH drug withdrawn worldwide Pfizer Canada is voluntarily withdrawing Thelin from the market worldwide due to concerns about hepatotoxicity. Lowering urate cuts cardiovascular deaths Hyperuricemia deserves more aggressive treatment, researcher says Teens: Cut the salt for future health Model predicts 3 g decrease in daily intake prevents thousands of cardiovascular events Huge trial backs cardiac resynchronization therapy Combined ICD-CRT device cuts mortality and heart failure hospitalizations Rivaroxaban takes off as alternative to warfarin ROCKET AF trial suggests drug offers more user-friendly anticoagulation in atrial fibrillation Wireless feedback aids BP control Patient involvement is key to the success of telemonitoring, say Canadian researchers Rosiglitazone: new Canadian restrictions Health Canada has issued new usage restrictions for rosiglitazone-containing products. Concomitant PPIs and antiplatelet agents OK First Previous 71 72 73 74 75 Next Last
